PDF(Pubmed)
Abstract：
Hepatocellular carcinoma (HCC) is a common malignancy with high mortality rates. While surgery can be curative in early-stage disease, 80% of patients cannot undergo surgical resection. Stereotactic body radiotherapy (SBRT), an emerging, non-invasive, precision treatment, has shown promising results across various stages of HCC and has thus been adopted in practice to varying degrees around the world. This article aims to review current guideline recommendations on SBRT, clinical evidence, and outcome comparisons with other local treatment modalities. Attempts are also made to compare the differences in clinical trials between Asian and Western countries.
摘要：
肝细胞癌（HCC）是一种常见的恶性肿瘤，死亡率高。虽然手术可以治愈早期疾病，80%的患者不能接受手术切除。立体定向身体放射治疗（SBRT），一个新兴的,非侵入性，精密治疗,在HCC的各个阶段都显示出了有希望的结果，因此在实践中在世界各地都得到了不同程度的采用。本文旨在回顾当前关于SBRT的指南建议，临床证据,以及与其他当地治疗方式的结果比较。还尝试比较亚洲和西方国家之间临床试验的差异。
